New study demonstrates the potential benefits of dressing regime improvements in delivering value-based chronic wound care
Barcelona, Spain. 28 March 2025. New study reports that switching patients with chronic wounds to the multi-layered, bordered silicone-coated foam dressing, Mepilex® Border Flex, alongside a clinician educational support programme, resulted in a significant reduction in the number of dressing changes being undertaken and a reduction in dressing-related costs.1
The study, sponsored by Mölnlycke Health Care, and conducted across primary care facilities in Seville, Spain was yesterday presented as an e-poster at the 35th Conference of the European Wound Management Association (EWMA) 2025 in Barcelona, Spain by the principal investigator Dr Andres Roldan Valenzuela, Centro de Salud Mairena del Aljarafe – Cuidad Expo, Seville.
The primary outcome of the study was a statistically significant reduction in the number of dressing changes undertaken, prior to and after the switch from a bordered foam dressing (baseline) to Mepilex® Border Flex; results demonstrated the median number of dressing changes reduced during the study period, from three in a seven-day period to just one.1
Other reported outcomes included:1
- 32% wounds healed by the final visit
- 50% reduction in wound area in four weeks in 75% of patients
- Two thirds (68.7%) reduction in wound area from baseline to the final visit
- Reduced pain at dressing changes (pain severity scores of 3.1 - 3.3 at baseline associated with previously used dressings, compared to scores of 0.5 - 1.1 recorded with Mepilex® Border Flex at the final visit)
- 44% reduction in weekly dressing cost per patient (5.38€ less after the dressing switch)
- No dressing related adverse events
Almost all (97%) of the clinicians rated the overall performance of Mepilex® Border Flex to be better than the previously used dressings, while 100% of patients rated Mepilex® Border Flex as ‘good’ to ‘very good’ in terms of overall satisfaction, compared to 65% for the previously used dressings.
Dr Andres Roldan Valenzuela, principal investigator commented “The results of this study clearly demonstrate how simple changes to a wound care treatment regime can bring about positive outcomes for both patients and healthcare providers. At a time when healthcare systems and staff are under increasing pressure on both cost and time it is encouraging that there are solutions to help drive efficiencies and improve outcomes for all involved.”
-Ends-
References
- Roldan Valenzuela A. et al. A wound dressing shows its value: clinical and economic effects of a dressing regime change for primary and home care chronic wound management. E-poster presentation at the 35th Conference of the European Wound Management Association (EWMA); Barcelona, Spain, 26-28 March 2025.Poster ID: ENG843
For more information, please contact:
Sofia Lindqvist
Media & Financial Communications Manager
Email: sofia.lindqvist@molnlycke.com
Phone: +4672 255 35 09
About the study design
The study involved 37 adult patients, aged between 30 and 90+ years presenting with wounds that had not reduced in size by >40-50% in the previous month and had been managed with foam dressing (other than Mepilex® Border Flex), for a minimum of four weeks (baseline). Category 2 pressure ulcers (24.3%) and venous leg ulcers (18.9%) were the most common wound types. Patients in the study had Mepilex® Border Flex applied to their wounds for ≥4 weeks, in conjunction with standard of care.
About Mölnlycke®
Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com
